Search

Displaying results 6791 - 6800 of 9333 in total
  1. Drug

    Pamufetinib

    go.drugbank.com/drugs/DB20752
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study).

  2. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    The product is intended for basal insulin treatment of diabetes mellitus.

  3. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.

  4. Drug

    Revexepride

    go.drugbank.com/drugs/DB20324
    Investigational

    The usage of the INN stem '-pride' in the name indicates that Revexepride is a sulpiride derivative and analogue.

  5. Drug

    Levcromakalim

    go.drugbank.com/drugs/DB21154
    Investigational

    The usage of the INN stem '-kalim' in the name indicates that Levcromakalim is a potassium channel activator, antihypertensive.

  6. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Luvometinib is a tyrosine kinase inhibitor.

  7. Drug

    Pebezertinib

    go.drugbank.com/drugs/DB21705
    Investigational

    The usage of the INN stem '-ertinib' in the name indicates that Pebezertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  8. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    The usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.

  9. Drug

    FRAX597

    go.drugbank.com/drugs/DB31734
    Experimental

    FRAX597 is a small molecule drug that inhibits the p21-activated kinases (PAKs).[A274673, A274678]

  10. Drug

    Ozekibart

    go.drugbank.com/drugs/DB18675
    Investigational

    Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.

    Synonyms: Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5).